Minimally invasive glaucoma surgery (MIGS) has been gaining popularity over the last 
INTRODUCTION
Over the last decade there has been significant activity in developing novel surgical treatments for glaucoma. These techniques and devices embrace the common theme of not only being effective in reducing intraocular pressure (IOP) and medication burden but also in causing as little trauma as possible to the target tissue, and most importantly they are safe. There is interest in finding surgical options that reduce surgical time, have an easily reproducible technique, and which are accessible to all ophthalmologists who manage glaucoma patients, rather than being the preserve of glaucoma specialists.
The term ''minimally invasive glaucoma surgery'' (MIGS) has arisen to describe such procedures; however, there is no widely accepted definition of MIGS, and thus no consensus on which specific procedures the term encompasses.
There has been particular interest recently in developing tubular stents, comprised of various materials, which can lower pressure in a similar manner to existing glaucoma drainage devices, but without the associated risks or the time-consuming and involved surgical procedure. Such new aqueous drainage devices can be classified on the basis of the targeted aqueous outflow pathway: via Schlemm's canal, via the suprachoroidal space, or via the subconjunctival space.
In this article we will describe the principle current glaucoma micro-implants, the currently available evidence underpinning their use, and how they may fit into future practice.
This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.
TRABECULAR MESHWORK BYPASS
Aqueous outflow resistance largely determines IOP, and the majority of this resistance is generated between the juxtacanalicular connective tissue and the inner wall of Schlemm's canal. Bypassing this region is, therefore, a viable method of decreasing IOP.
iStent
The iStent (Glaukos Corporation, Laguna Hills, CA, USA) is a heparin-coated non-ferromagnetic titanium device (Fig. 1 Medication reduction is another benefit of this procedure. The mean decrease in medications compared to screening in this trial was greater in the treatment group (1.4 ± 0.8 mmHg) versus the control group (1.0 ± 0.8) at 12 months (P = 0.005). This is significant not only for the patients' convenience and compliance, but importantly for the protection of their ocular surface and for the potential success of future drainage surgery.
The reduction in ocular hypotensives was still numerically larger at 24 months in favour of the stent group, although no longer statistically significant. In the stent group, 15% were receiving medications at month 12, compared to 35% of the cataract only group (P = 0.001). groups, but did show a significant difference in the mean number of postoperative medications [9] . A recent study by Katz et al. published a prospective study of 119 patients randomized to one, two, or three iStents. All but one of these patients was phakic, and the procedure was not combined with cataract surgery. At 18 months, mean unmedicated IOP was 15.9 ± 0.9 mmHg in one-stent subjects, 14.1 ± 1.0 mmHg in two-stent subjects, and 12.2 ± 1.1 mmHg in three-stent subjects. Intraocular pressure reduction was significantly greater with implantation of each additional stent (P\0.001) [10] .
With the view that multiple stents appear to be superior, Glaukos have manufactured a second-generation iStent, termed the iStent Inject. The single-use injector is designed to be used left-or right-handed, and comes pre-loaded with two stents. The stents are designed to be ''bullet'' rather than L-shaped.
Initial laboratory studies confirmed that this device increased outflow facility [11] . In clinical use, insertion of two iStent Injects alone had the same efficacy as adding a second-line medication in patients uncontrolled on one medication [12] . Voskanyan et al. further demonstrated that in patients with IOP not controlled on two medications, two iStent Injects alone produced an IOP B18 mmHg without medications in 66% of subjects at 12 months [13] .
The safety profile with this procedure appears to be excellent, with no major complications reported in the literature.
Hydrus
The Hydrus Microstent (Ivantis Inc, Irvine, CA, USA) is a trabecular bypass device and Schlemm's canal scaffold ( 
SUPRACHOROIDAL SPACE
The suprachoroidal space is an intriguing target for the development of new procedures. There are several reasons to suppose that targeting this pathway might be successful. Firstly, the most effective topical hypotensive medications, the prostaglandins, exert their effect via this pathway [19] . Secondly, it is known that there is a negative pressure gradient that drives aqueous humor in the direction of the suprachoroidal space [20] . Thirdly, it has long been known that producing a cyclodialysis cleft lowers the pressure [21] . Consequently, there have been numerous attempts to develop a surgical technique to exploit this possibility. It had previously proven difficult to find a safe and accessible surgical technique that produces stable long-term results without the hypotony and rebound high pressure associated with cyclodialysis. The first published study on Cypass looked at its efficacy when combined with cataract surgery in two groups of patients [22] . 
SUBCONJUNCTIVAL SPACE
The subconjunctival space is the traditional outflow pathway for glaucoma drainage surgery. Successful surgery depends on the continued patency of a pathway for aqueous humor, and on the scarring response in the conjunctiva (Fig. 4) .
XEN GEL Implant
The XEN GEL Implant (AqueSys Inc., Aliso Viejo, CA, USA) is a 6-mm cylinder of It comes pre-loaded in the injector and is implanted ab interno, creating a drainage pathway between the anterior chamber and subconjunctival space. The procedure is often augmented with subconjunctival injection of mitomycin-C. Long-term animal studies have shown the Xen implant structure to be stable over several years [26] . It softens on contact with water within 1-2 min, meaning that it can bend and conform to tissue, reducing the risk of erosion. Microforce testing has shown the XEN 45 to be more than 100 times as flexible as a typical silicone shunt tube [27] . Although initially produced with three different lumen diameters, the tube with the 45-nm lumen size is the only device now recommended for implantation by the manufacturer. This lumen size was chosen in an effort to design a device with the necessary dimensions to prevent postoperative hypotony by the primary flow resistance of the tube itself [28] . The tube length of 6 mm was identified as the ideal length for passage ab interno from the trabecular meshwork to the subconjunctival space at an optimal distance from the limbus. In another pilot study on XEN 140 insertion as a standalone procedure [30] in 49 eyes, 40% of patients had an outcome classified as an unqualified success at 12 months, achieving an IOP B18 mmHg and C20% reduction in IOP, with 89% being successful when those on medications were included, despite a high proportion of patients having had a previous failed trabeculectomy.
These studies are not directly comparable to the currently recommended device and technique, however. As well as having larger lumen size, neither study used subconjunctival mitomycin C at the time of implant insertion. This is likely to have affected the degree of scarring, and therefore the outcome in terms of pressure, due to increased conjunctival resistance, and also the number of postoperative needling interventions required. There were no serious adverse events attributed to the device in either study. At postoperative IOPs were 13.1 ± 3.6 mmHg at 12 months (p\0.001) [31] . Mean number of preoperative medications was 2.7 ± 1, and this reduced to 0.9 ± 1.1 (p\0.001) at 12 months.
There were no complications.
InnFocus
The InnFocus Microshunt (InnFocus Inc, Miami, FL, USA), formerly known as the MIDI Arrow, is an aqueous drainage shunt designed to be implanted ab externo. As a fornix-based conjunctival flap and dissection of a shallow scleral pocket is required, unlike the other devices covered in this review, it resembles conventional trabeculectomy more than MIGS.
Of interest, however is the product's material construction. Fig. 5 Comparison of the pressure-lowering effect of (1) combined phacoemulsification and iStent [2], (2) combined phacoemulsification and Hydrus [16] , (3) CyPass alone [25] , (4) XEN 45 alone [31] , and (5) InnFocus alone [33] to less postoperative conjunctival fibrosis.
During development, however, it was found that the fins designed to prevent tube migration could erode through the conjunctiva-hence, the need for a scleral pocket. A study of 23 eyes with Microshunt insertion, some with and some without cataract surgery, showed that over 80% of the patients had had an IOP B14 mmHg at 3 years [33] . At 3 years, the number of medications had fallen from 2.6 ± 0.9 to 0.8 ± 1.2 in the eyes with Microshunt alone, and from 2.0 ± 0.9 to 0.4 ± 0.1 in the eyes that underwent a combined procedure. In the group as a whole, the mean IOP at 3 years was 10.7 ± 3.5 mmHg and the qualified success rate (IOP B14 mmHg and IOP reduction C20%) was 95%. The most common complications were transient hypotony (13%) and transient choroidal effusion (8.7%), which all resolved spontaneously. There were no leaks, infections, migrations, erosions, persistent corneal oedema, or serious long-term adverse events. 
DISCUSSION
The large number of new glaucoma drainage devices emerging in recent years is a testament to both the desire to find a safe and simple surgical procedure to treat mild to moderate glaucoma, and also to the inability of any one procedure to establish itself as filling this need.
Studies comparing a single iStent inserted at the time of cataract surgery to cataract surgery alone showed statistically significant but relatively modest additional reductions in pressure. The reduction in the number of medications is beneficial, however, and is more promising for the iStent finding a place in clinical practice given the ease of application.
There are also new roles found for iStent use in other ways than as simply an adjunct to cataract surgery. There are several studies supporting its Similarly, subconjunctival drainage microstents should not be considered a direct replacement for traditional drainage surgery, as they do not appear to be able to achieve the lower target pressures needed for some patients, but the safety profile may prove to be such that a XEN implant is justifiable in a patient for whom a trabeculectomy was not, and not all patients need a pressure of 10 mmHg. Another consideration that will certainly influence the uptake of new procedures is their economic benefit. In an economic analysis of iStent use in the Canadian medical system [35] , cost savings of Can$20.77, Can$1,272.55, and Can$2,124.71 per patient were estimated over 6 years, when comparing two iStents versus mono-, bi-, and triple therapy, respectively. Two stents plus one medication still showed savings over two or three drops. In the CyPass study described above, 83% of uncontrolled patients did not require trabeculectomy after
CyPass insertion as a standalone procedure. This is likely to be associated with significant savings in theatre time and follow-up appointments, and similar savings have been discussed with the use of subconjunctival space stents. Nonetheless data to support the above does not currently exist in the literature.
CONCLUSION
The rapid influx of new devices onto the market in recent years has caused some to wonder whether we are entering a new era of microstent surgery in glaucoma management. The results of large prospective randomised studies are still awaited for many of the most promising devices. It will be interesting to see whether the ''trabeculectomy holiday'' that followed the introduction of prostaglandin analogues is repeated. It is more likely that, rather than replacing older treatments, new treatments will find their own niche depending on their respective risks and benefits. This has always been the case and the process of technological advance is on-going, bringing new treatments to challenge those discussed above. Future developments, such as the anticipated drug-eluting implants, will rekindle the debate.
